Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Single-dose dalbavancin and patient satisfaction in an outpatient setting in the treatment of acute bacterial skin and skin structure infections.

Rappo U, Gonzalez PL, Puttagunta S, Akinapelli K, Keyloun K, Gillard P, Liu Y, Dunne MW.

J Glob Antimicrob Resist. 2019 Jun;17:60-65. doi: 10.1016/j.jgar.2019.02.007. Epub 2019 Feb 20.

2.

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety.

Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, Suen A, Mas Casullo V, Melnick D, Miceli R, Kovacevic M, De Bock G, Dunne MW.

Open Forum Infect Dis. 2018 Dec 10;6(1):ofy331. doi: 10.1093/ofid/ofy331. eCollection 2019 Jan.

3.

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs.

Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW.

Drugs Context. 2018 Dec 11;7:212559. doi: 10.7573/dic.212559. eCollection 2018.

4.

In Vitro Activity of Sulopenem, an Oral Penem, against Urinary Isolates of Escherichia coli.

Karlowsky JA, Adam HJ, Baxter MR, Denisuik AJ, Lagacé-Wiens PRS, Walkty AJ, Puttagunta S, Dunne MW, Zhanel GG.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01832-18. doi: 10.1128/AAC.01832-18. Print 2019 Jan.

5.

Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age.

Gonzalez D, Bradley JS, Blumer J, Yogev R, Watt KM, James LP, Palazzi DL, Bhatt-Mehta V, Sullivan JE, Zhang L, Murphy J, Ussery XT, Puttagunta S, Dunne MW, Cohen-Wolkowiez M.

Pediatr Infect Dis J. 2017 Jul;36(7):645-653. doi: 10.1097/INF.0000000000001538.

6.

Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative Studies.

Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S.

Drug Saf. 2016 Feb;39(2):147-57. doi: 10.1007/s40264-015-0374-9. Review.

7.

A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection.

Dunne MW, Puttagunta S, Giordano P, Krievins D, Zelasky M, Baldassarre J.

Clin Infect Dis. 2016 Mar 1;62(5):545-51. doi: 10.1093/cid/civ982. Epub 2015 Nov 26.

8.

Efficacy of dalbavancin in the treatment of MRSA rat sternal osteomyelitis with mediastinitis.

Barnea Y, Lerner A, Aizic A, Navon-Venezia S, Rachi E, Dunne MW, Puttagunta S, Carmeli Y.

J Antimicrob Chemother. 2016 Feb;71(2):460-3. doi: 10.1093/jac/dkv357. Epub 2015 Oct 30.

PMID:
26518048
9.

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects.

Scoble PJ, Owens RC Jr, Puttagunta S, Yen M, Dunne MW.

Clin Drug Investig. 2015 Dec;35(12):785-93. doi: 10.1007/s40261-015-0340-4.

10.

In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program.

McCurdy SP, Jones RN, Mendes RE, Puttagunta S, Dunne MW.

Antimicrob Agents Chemother. 2015 Aug;59(8):5007-9. doi: 10.1128/AAC.00274-15. Epub 2015 May 18.

11.

Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studies.

Dunne MW, Sahm D, Puttagunta S.

Ann Clin Microbiol Antimicrob. 2015 Apr 2;14:19. doi: 10.1186/s12941-015-0081-5.

12.

Surrogate analysis of vancomycin to predict susceptible categorization of dalbavancin.

Jones RN, Farrell DJ, Flamm RK, Sader HS, Dunne MW, Mendes RE.

Diagn Microbiol Infect Dis. 2015 May;82(1):73-7. doi: 10.1016/j.diagmicrobio.2015.01.017. Epub 2015 Feb 7.

PMID:
25724854
13.

A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin-structure infections.

Dunne MW, Zhou M, Darpo B.

Int J Antimicrob Agents. 2015 Apr;45(4):393-8. doi: 10.1016/j.ijantimicag.2014.12.021. Epub 2015 Jan 22.

14.

Extended-duration dosing and distribution of dalbavancin into bone and articular tissue.

Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J.

Antimicrob Agents Chemother. 2015 Apr;59(4):1849-55. doi: 10.1128/AAC.04550-14. Epub 2015 Jan 5.

15.

Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.

Sagara I, Oduro AR, Mulenga M, Dieng Y, Ogutu B, Tiono AB, Mugyenyi P, Sie A, Wasunna M, Kain KC, Djimdé AA, Sarkar S, Chandra R, Robbins J, Dunne MW.

Malar J. 2014 Nov 25;13:458. doi: 10.1186/1475-2875-13-458.

16.

Dalbavancin or oritavancin for skin infections.

Boucher HW, Talbot GH, Dunne MW.

N Engl J Med. 2014 Sep 18;371(12):1161-2. doi: 10.1056/NEJMc1407925. No abstract available.

PMID:
25229922
17.

Once-weekly dalbavancin versus daily conventional therapy for skin infection.

Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW.

N Engl J Med. 2014 Jun 5;370(23):2169-79. doi: 10.1056/NEJMoa1310480.

18.

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.

Fätkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, Lampiris H, Hirschel B, Tebas P, Raffi F, Trottier B, Bellos N, Saag M, Cooper DA, Westby M, Tawadrous M, Sullivan JF, Ridgway C, Dunne MW, Felstead S, Mayer H, van der Ryst E; MOTIVATE 1 and MOTIVATE 2 Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1442-55. doi: 10.1056/NEJMoa0803154.

19.

Maraviroc for previously treated patients with R5 HIV-1 infection.

Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, Nadler J, Clotet B, Karlsson A, Wohlfeiler M, Montana JB, McHale M, Sullivan J, Ridgway C, Felstead S, Dunne MW, van der Ryst E, Mayer H; MOTIVATE Study Teams.

N Engl J Med. 2008 Oct 2;359(14):1429-41. doi: 10.1056/NEJMoa0803152.

20.

Real-time PCR assay for rapid detection and analysis of PfCRT haplotypes of chloroquine-resistant Plasmodium falciparum isolates from India.

Keen J, Farcas GA, Zhong K, Yohanna S, Dunne MW, Kain KC.

J Clin Microbiol. 2007 Sep;45(9):2889-93. Epub 2007 Jul 3.

21.

In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.

Sidhu AB, Sun Q, Nkrumah LJ, Dunne MW, Sacchettini JC, Fidock DA.

J Biol Chem. 2007 Jan 26;282(4):2494-504. Epub 2006 Nov 15.

22.

Metabolic syndrome, C-reactive protein, and prognosis in patients with established coronary artery disease.

Aguilar D, Fisher MR, O'Connor CM, Dunne MW, Muhlestein JB, Yao L, Gupta S, Benner RJ, Cook TD, Edwards D, Pfeffer MA; Investigators in the Weekly Intervention with Zithromax for Atherosclerosis and its Related Disorder study.

Am Heart J. 2006 Aug;152(2):298-304.

PMID:
16875914
23.

A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India.

Dunne MW, Singh N, Shukla M, Valecha N, Bhattacharyya PC, Patel K, Mohapatra MK, Lakhani J, Devi CU, Adak T, Dev V, Yadav RS, Lele C, Patki K.

Am J Trop Med Hyg. 2005 Dec;73(6):1108-11.

PMID:
16354821
24.

Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.

Girard D, Finegan SM, Dunne MW, Lame ME.

J Antimicrob Chemother. 2005 Aug;56(2):365-71. Epub 2005 Jul 7.

PMID:
16002421
25.

A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India.

Dunne MW, Singh N, Shukla M, Valecha N, Bhattacharyya PC, Dev V, Patel K, Mohapatra MK, Lakhani J, Benner R, Lele C, Patki K.

J Infect Dis. 2005 May 15;191(10):1582-8. Epub 2005 Apr 11.

PMID:
15838784
26.
27.

Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial.

O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD; Investigators in the WIZARD Study.

JAMA. 2003 Sep 17;290(11):1459-66.

PMID:
13129985
28.

Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media.

Dunne MW, Latiolais T, Lewis B, Pistorius B, Bottenfield G, Moore WH, Garrett A, Stewart TD, Aoki J, Spiegel C, Boettger D, Shemer A.

J Antimicrob Chemother. 2003 Sep;52(3):469-72. Epub 2003 Jul 29.

PMID:
12888586
29.

Efficacy of single-dose azithromycin in treatment of acute otitis media in children after a baseline tympanocentesis.

Dunne MW, Khurana C, Mohs AA, Rodriguez A, Arrieta A, McLinn S, Krogstad JA, Blatter M, Schwartz R, Vargas SL, Emparanza P, Fernandez P, Gooch WM 3rd, Aspin M, Podgore J, Roine I, Blumer JL, Ehrlich GD, Chow J.

Antimicrob Agents Chemother. 2003 Aug;47(8):2663-5.

31.

Single dose of azithromycin or three-day course of ciprofloxacin as therapy for epidemic dysentery in Kenya. Acute Dysentery Study Group.

Shanks GD, Smoak BL, Aleman GM, Oundo J, Waiyaki PG, Dunne MW, Petersen L.

Clin Infect Dis. 1999 Oct;29(4):942-3. No abstract available.

PMID:
10589921
32.

Azithromycin as treatment for disseminated Mycobacterium avium complex in AIDS patients.

Koletar SL, Berry AJ, Cynamon MH, Jacobson J, Currier JS, MacGregor RR, Dunne MW, Williams DJ.

Antimicrob Agents Chemother. 1999 Dec;43(12):2869-72.

33.

Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group.

Dunne MW, Bozzette S, McCutchan JA, Dubé MP, Sattler FR, Forthal D, Kemper CA, Havlir D.

Lancet. 1999 Sep 11;354(9182):891-5.

PMID:
10489947
34.

Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS.

Havlir DV, Dubé MP, McCutchan JA, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Kumar PN, White AC Jr, Witt MD, Nightingale SD, Sepkowitz KA, MacGregor RR, Cheeseman SH, Torriani FJ, Zelasky MT, Sattler FR, Bozzette SA.

Clin Infect Dis. 1998 Dec;27(6):1369-75.

PMID:
9868644
35.

Once weekly azithromycin therapy for prevention of Mycobacterium avium complex infection in patients with AIDS: a randomized, double-blind, placebo-controlled multicenter trial.

Oldfield EC 3rd, Fessel WJ, Dunne MW, Dickinson G, Wallace MR, Byrne W, Chung R, Wagner KF, Paparello SF, Craig DB, Melcher G, Zajdowicz M, Williams RF, Kelly JW, Zelasky M, Heifets LB, Berman JD.

Clin Infect Dis. 1998 Mar;26(3):611-9.

PMID:
9524832
36.

Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group.

Havlir DV, Haubrich R, Hwang J, Dunne MW, Currier J, Forthal D, Torriani F, Richman DD, McCutchan JA.

J Infect Dis. 1998 Mar;177(3):595-9.

PMID:
9498437
37.

Successful double-blinded, randomized, placebo-controlled field trial of azithromycin and doxycycline as prophylaxis for malaria in western Kenya.

Andersen SL, Oloo AJ, Gordon DM, Ragama OB, Aleman GM, Berman JD, Tang DB, Dunne MW, Shanks GD.

Clin Infect Dis. 1998 Jan;26(1):146-50.

PMID:
9455524
38.

Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group.

Havlir DV, Dubé MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC Jr, Witt MD, Bozzette SA, McCutchan JA.

N Engl J Med. 1996 Aug 8;335(6):392-8.

Supplemental Content

Loading ...
Support Center